Please address all inquiries to:
Gastro Hep Advances Editorial Office
American Gastroenterological Association
4930 Del Ray Avenue
Bethesda, MD 20814-3015
Phone: (301) 941-9781
[email protected]

Gastro Hep Advances is the newest peer-reviewed journal published by the American Gastroenterological Association (AGA), joining Gastroenterology, Clinical Gastroenterology and Hepatology (CGH), Cellular and Molecular Gastroenterology and Hepatology (CMGH), and Techniques and Innovations in Gastrointestinal Endoscopy (TIGE). Gastro Hep Advances is a broad-scope, online-only, open access journal that publishes papers on basic, clinical, and translational gastroenterology and hepatology. The open access model enables authors with funding mandates to have a high-quality home for their research.

In addition to full-length original research articles, the journal publishes comprehensive reviews, commentaries, and editorials. A core objective is to publish papers cascaded from AGA's other journals that represent outstanding science and therefore qualify for publication in a journal supported by the AGA brand. Gastro Hep Advances also strongly encourages the submission of manuscripts not originally submitted to the other AGA journals. Gastro Hep Advances' aim is to publish digestive disease research that is technically, ethically, and scientifically sound rather than to focus on subjective perceptions of significance and novelty.

Manuscripts must be prepared in accordance with the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" developed by the International Committee of Medical Journal Editors (http://www.icmje.org). Gastro Hep Advances is a member of the Committee on Publication Ethics (COPE) (http://www.publicationethics.org).

Shortly after articles are accepted, they are posted to the "Articles in Press" page of the journal's website. As a new journal, Gastro Hep Advances is not yet indexed in PubMed. At present, only federally funded research will be deposited into PubMed Central, which satisfies the National Institutes of Health access policy. Application and admission into PubMed Central - which would permit depositing of all accepted articles, regardless of funding status - is a major strategic goal of the journal and we are diligently working towards.The journal's website also supports multimedia files and supplemental data, including images, video, and audio files. Gastro Hep Advances provides updates and commentary via Facebook and Twitter.

Information about Article Types
Submission Checklist
Preprint Server Policy
Data Transparency Policy
Graphical Abstracts
Manuscript Processing and Review
Appeals Policy
Publication
Ethical Standards
Conflict of Interest Policy
Plagiarism, Duplicate Submission/Publication Policy
Image Manipulation Policy
Open Access Policies
Clinical Trials
Reporting Meta-Analyses of Genetic Studies
Distribution of Material Described in Published Papers


INFORMATION ABOUT ARTICLE TYPES

**All manuscripts must be submitted via http://www.editorialmanager.com/ghadvances.**

Original Articles
Original Articles are full-length reports of original research. Articles cover topics relevant to clinical, basic, and translational studies. Submissions must adhere to the following guidelines:
  • Manuscript: New manuscripts can be uploaded as a single PDF with figures and tables placed at the appropriate locations within the text and/or as separate files. Separate files are required for all revised manuscripts to facilitate publication.
  • Title page: Title; authors' names; authors' institutions; corresponding author contact information; conflict of interest statement (for all authors); description of how each author contributed to the manuscript; statement if article received funding; statement of whether data, analytic methods, and study materials will or will not be made available to other researchers. If study materials will be made available, specify where they will be made available.
  • Word count: Maximum of 7000 words (inclusive of main text; references; table/figure legends).
  • Abstract: Maximum of 260 words, structured as follows: Background and Aims; Methods; Results; Conclusion; 4 to 5 keywords.
  • Tables/figures: Maximum of 7 tables (no panels) and/or figures.
    • Please submit figures as separate attachments in JPEG, TIFF, EPS, or PDF formats (300 ppi resolution).
    • Please clearly label file names of tables and figures (eg, Table 1.docx; Figure 1.jpg).
    • The editor reserves the right to publish excessively long tables as online-only material.
  • References:Gastro Hep Advances requires authors to identify underlying or relevant datasets in their manuscript by citing them in the text and including a data reference in the reference list. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add "[dataset]" immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.
  • Randomized controlled trials: Provide CONSORT checklist and patient flowchart as supplemental attachments.
  • Clinical trials
    • Provide the clinical trial registry website and trial number at the end of the "conclusions" section of the abstract.
    • Include a statement in the "methods" section of the manuscript affirming that "all authors had access to the study data and reviewed and approved the final manuscript."
    • Include the clinical trial protocol in English as a supplemental attachment.
    • Gastro Hep Advances requires that clinical trial reports address the authors' intent to share deidentified individual participant data. To that end, authors must include a data sharing statement on the title page under the heading "Data Transparency Statement." The statement should include the following information:
      • Whether deidentified individual participant data will be shared
      • Which particular data will be shared
      • Any additional documents that will be shared
      • The method through which data will be shared
      • The time frame during which data will be accessible
      • The conditions, if any, required to access to the data
      • "Deidentified individual participant data are available indefinitely at www.example.org. The study protocol, analytic code?[etc] are also available at the same website."
      • "Deidentified individual participant data that underlie the reported results will be made available 3 months after publication for a period of 5 years after the publication date at www.example.org. The study protocol is included as a data supplement available with the online version of this article."
      • "Individual participant data will not be shared."
    • Registration
      • In accordance with the guidelines set forth by ICMJE, authors of manuscripts involving clinical trials must provide full registration of their trial(s). A clinical trial is defined as any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. The trial must have at least 1 prospectively assigned concurrent control or comparison group in order to trigger the requirement for registration. Appropriate online registries include https://clinicaltrials.gov/, http://www.isrctn.com/, http://www.umin.ac.jp/ctr/index.htm, http://www.anzctr.org.au/, and http://www.trialregister.nl/trialreg/index.asp or any primary registry that participates in the World Health Organization's International Clinical Trial Platform.


Research Letters
Research Letters are concise, meritorious scientific reports of original research. These reports are not the same as a Letter to the Editor and must not duplicate other material published or submitted for publication. Submissions must adhere to the following guidelines: 6
  • Manuscript: New manuscripts can be uploaded as a single PDF with figures and tables placed at the appropriate locations within the text and/or as separate files. Separate files are required for all revised manuscripts to facilitate publication.
  • Title page: Title; authors' names; authors' institutions; corresponding author contact information; conflict of interest statement (for all authors); statement if article received funding; statement if data, analytic methods, and study materials will or will not be made available to other researchers. If study materials will be made available, specify where they will be made available.
  • Word count: Article text must not exceed 1000 words (not including table/figure legends or references).
    • No section headings should be included in the manuscript (eg, do not include section headings such as "Methods" or "Results").
    • Article titles should be declarative.
    • 1000 words of supplemental text may be included for describing methods. The text cannot be used to provide additional results or discussion.
  • Abstract: No abstract.
  • Tables/figures: May include up to 2 figures or tables.
    • Please submit figures as separate attachments in JPEG, TIFF, EPS, or PDF formats (300 ppi resolution).
    • An additional 4 figures or tables (with legends of no more than 500 words each) for describing results may be included as supplementary material.
    • Please clearly label file names of tables, figures, and supplementary materials (eg, Table 1.docx; Figure 1.jpg; Supplementary Figure 1.tif).
  • References: Limited to 10.
    • Format: Jones RS, et al. Gastroenterology 2011;2:373-380 (only the first author is listed, unless manuscripts with joint first authors are cited, and the article title is not included).
    • An additional 20 references for describing results may be included as supplementary material.
    • Gastro Hep Advances requires authors to cite underlying or relevant datasets in their manuscript by citing them in the text and including a data reference in the reference list. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add "[dataset]" immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.


Image of the Month
This section presents striking images that are meant to challenge and inform the reader. The text should succinctly present relevant clinical information, including a short description of the patient's history, relevant findings, clinical course, response to treatment, and condition at last follow-up. Endoscopy images should be free of lettering, words, or numbering and associated pathology images should be included when appropriate. Submissions must adhere to the following guidelines:
  • Manuscript: New manuscripts can be uploaded as a single PDF with figures and tables placed at the appropriate locations within the text and/or as separate files. Separate files are required for all revised manuscripts to facilitate publication.
  • Title page: title; authors' names (limit of 3); authors' institutions; corresponding author contact information; conflict of interest statement (for all authors).
  • Title should be declarative and succinct. Editors may modify the title according to journal style.
  • Word count: 200 words.
  • Abstract: No abstract.
  • References: No references.
  • Figures: 4 figures (no panels) total. No figure legends/image captions, all pertinent information must be included in main text.
  • Please submit figures as separate attachments in JPEG, TIFF, EPS, or PDF formats (300 PPI resolution).


Case Reports
Case Reports detail and analyze a particular case that may be of interest to Gastro Hep Advances' readership. Submissions must adhere to the following guidelines:
  • Manuscript: New manuscripts can be uploaded as a single PDF with figures and tables at the appropriate point within the text and/or as separate files. Separate files will be required for all revised manuscripts in order to facilitate publication.
  • Title page: Title; authors' names; authors' institutions; corresponding author contact information; conflict of interest statement (for all authors); statement if article received funding.
  • Word count: Article text must not exceed 1000 words (not including table/figure legends or references).
    • Section headings should include: Abstract, Introduction, Case Report, Discussion, References.
  • Abstract: 100 words, unstructured.
  • Tables/Figures: May include up to 6 tables, figures, or video.
    • Please submit figures as separate attachments in JPEG, TIFF, EPS, or PDF formats (300 PPI resolution).
    • Please clearly label file names of tables, figures, and supplementary materials (eg, Table 1.docx; Figure 1.jpg; Supplementary Figure 1.tif).
  • References: Limited to 20.
    • Format: Jones RS, et al. Gastroenterology 2011; 2: 373 -380 (only the first author is listed, unless manuscripts with joint first authors are cited, and article title is not included).
    • Gastro Hep Advances requires authors to cite underlying or relevant datasets in their manuscript by citing them in the text and including a data reference in the Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.


Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analyses are manuscripts that feature an organized and detailed review of the scientific literature about a particular topic. For meta-analyses of randomized controlled trials, authors must provide a CONSORT checklist at manuscript submission and follow the PRISMA reporting guidelines found here: http://prisma-statement.org/. For meta-analyses of observational studies, authors must follow the MOOSE reporting guidelines found here: http://www.editorialmanager.com/jognn/account/MOOSE.pdf. Submissions must adhere to the following guidelines:
  • Manuscript: New manuscripts can be uploaded as a single PDF with figures and tables placed at the appropriate locations within the text and/or as separate files. Separate files are required for all revised manuscripts to facilitate publication.
  • Title page: Title; authors' names; authors' institutions; corresponding author contact information; conflict of interest statement (for all authors); description of how each author contributed to the manuscript; statement if article received funding; statement if data, analytic methods, and study materials will or will not be made available to other researchers. If study materials will be made available, specify where they will be made available.
  • Word count: Maximum of 6000 words (inclusive of main text, references, and table/figure legends).
  • Abstract: Maximum of 260 words, structured as follows: Background and Aims; Methods; Results; Conclusion; 4 to 5 keywords.
  • Tables/figures: Maximum of 6 tables (no panels) and/or figures.
    • Please submit figures as separate attachments in JPEG, TIFF, EPS, or PDF formats (300 ppi resolution).
    • Please clearly label file names of tables and figures (eg, Table 1.docx; Figure 1.jpg).
  • Randomized controlled trials: Provide CONSORT checklist as a supplemental attachment.
  • References: Gastro Hep Advances requires authors to cite underlying or relevant datasets in their manuscript by citing them in the text and including a data reference in the reference list. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add "[dataset]" immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.


Narrative Reviews
Narrative Reviews discuss a particular topic of interest to the Gastro Hep Advances readership.
  • Manuscript: New manuscripts can be uploaded as a single PDF with figures and tables placed at the appropriate locations within the text and/or as separate files. Separate files are required for all revised manuscripts to facilitate publication.
  • Title page: Title; authors' names; authors' institutions; corresponding author contact information; conflict of interest statement (for all authors);description of how each author contributed to the manuscript; statement if article received funding.
  • Word count: Maximum of 6000 words (includes main text only).
  • Abstract: Maximum of 260 words, unstructured.
  • References: Limited to 150.
  • Tables/figures: Maximum of 6 tables (no panels) and/or figures.
    • Please submit figures as separate attachments in JPEG, TIFF, EPS, or PDF formats (300 ppi resolution).
    • Additional tables/figures may be included as supplementary items.
    • Please clearly label file names of tables, figures, and supplementary materials (eg, Table 1.docx; Figure 1.jpg; Supplementary Figure 1.tif).


Correspondence
Letters to the Editor allow the opportunity to offer novel perspectives and opinions on full-length original research articles and research letters published in Gastro Hep Advances. Letters must be submitted for consideration by the end of the month in which the corresponding article was included in an issue (eg, a response to an article in the July issue should be submitted by the end of July). Submissions must adhere to the following guidelines:
  • Title page: Title; authors' names; authors' institutions; corresponding author contact information; conflict of interest statement (for all authors); statement if article received funding; author name, article title, and (if available) DOI of the original article your correspondence is responding to.
  • Word count: Maximum of 750 words (inclusive of main text and table/figure legends).
  • Abstract: Not required.
  • Tables/figures: Not permitted.
  • References: Limited to 8.
    • Format: Jones RS, et al. Gastroenterology 2011;2:373-380 (only the first author is listed, unless manuscripts with joint first authors are cited, and the article title is not included).


Editorials
This article type is solicited by the board of editors and no unsolicited submissions will be considered.

Commentaries
Commentaries express perspectives or provide information on current topics of interest in the field of gastroenterology and hepatology. They may be solicited or unsolicited.
  • Manuscript: New manuscripts can be uploaded as a single PDF with figures and tables placed at the appropriate locations within the text and/or as separate files. Separate files are required for all revised manuscripts to facilitate publication.
  • Title page: Title; authors' names; authors' institutions; corresponding author contact information; conflict of interest statement (for all authors); statement if article received funding.
  • Abstract: Not permitted.
  • Word count: Maximum of 2400 words (inclusive of main text and table/figure legends).
  • Tables/figures: Maximum of 2 tables (no panels) and/or figures.
    • Please submit figures as separate attachments in JPEG, TIFF, EPS, or PDF formats (300 ppi resolution).
    • Please clearly label file names of tables and figures (eg, Table 1.docx; Figure 1.jpg.
  • References: Limited to 25.


SUBMISSION CHECKLIST

**All manuscripts must be submitted via http://www.editorialmanager.com/ghadvances.**

All manuscripts should be Microsoft Word documents with double-spaced text and should contain the following sections in the order given:

Cover Letter
Gastro Hep Advances strongly encourages authors to provide a concise introductory statement describing their manuscript and any relevant contextual information. Please note that the Cover Letter should not serve as the Title Page of your manuscript document. In addition, authors should suggest 2 to 5 reviewers (including email addresses and phone numbers) and the associate editor they believe is best qualified to review the paper. Authors may also list nonpreferred associate editors or reviewers, but the ultimate decision is at the sole discretion of the editor-in-chief and associate editor, respectively. Please be sure to state the reasons for any potential deviations from standard format and clarify any potential conflicts related to the exclusive nature of the publication.

Title Page
A Title Page must be included as the first page of the manuscript document. It should contain the following sections in the order given:
  • Title: Include animal species; use no abbreviations; limit to 120 characters (with spaces).
  • Short title: Limited to 45 characters (with spaces).
  • Author(s): List full names of all authors; their positions and institutions; and location of department and institution where the work was performed.
  • Grant support: List grant support and other assistance.
  • Abbreviations: List abbreviations (in alphabetical order) not mentioned in the Style Guide following the Instructions to Authors. (Note: In general, the use of abbreviations is discouraged).
  • Correspondence: Provide contact information (ie, name, physical address, email address, telephone, and fax numbers) of the corresponding author.
  • Disclosures: List any potential conflicts (financial, professional, or personal) relevant to the manuscript. If an author has nothing to disclose, this must be stated.
  • Transcript profiling: List accession number of repository for expression microarray data.
  • Writing assistance: List names and funding source for individuals who provided writing assistance.
  • Data transparency statement: Statement of whether data, analytic methods, and study materials will or will not be made available to other researchers. If study materials will be made available, specify where they will be made available.


Corresponding Author Duties
When submitting a manuscript, the corresponding author should be prepared to complete the following steps:
  • Have an account on editorialmanager.com/ghadvances with a current email address.
  • Upload the manuscript files and provide information on the region of origin, the category of the manuscript, keywords, and classifications relevant to the manuscript's focus area.
  • If prompted, propose suggested reviewers, and/or note opposed reviewers for consideration by the board of editors. Please note the board of editors is not obligated to follow your suggestions.
  • Answer several questions regarding the composition of the manuscript, and attest to statements certifying the validity of the data, funding sources, and intellectual content. Authors shall be offered a choice of the following user licenses to be applied to Articles where they appear on the Publisher's online platforms:
  • Coauthor names, academic degrees, and email addresses are required and must be added to the Editorial Manager system separate from inclusion within the Word document file of the manuscript. ORCID numbers may also be included for you and/or your coauthors, if applicable.
  • Respond promptly to all correspondence related to the submission, including requests from the editorial office regarding changes to comply with article type guidelines (if applicable). If the manuscript is accepted, the corresponding author will receive the proof from our publisher and must supply all edits within 48 hours.


Abstract
An Abstract should be included after the Title Page. It should not exceed 260 words or include any footnotes or references. Abbreviations should be avoided and spelled out at first mention. If your article type requires a structured abstract (see earlier), it should be organized as follows:
  • Background and Aims: Describe the importance of the study and the precise research objective(s) or study question(s).
  • Methods: Include information on the following aspects of study design when applicable. The methods section may employ subheadings at the discretion of the author.
    • Design: Describe the basic study design (eg, randomized controlled trial, cross sectional study, cohort study, case series, survey, etc). Source of all nonstandard reagents need to be explicitly stated.
    • Setting: Specify whether the study was conducted in a primary or tertiary care setting, in an ambulatory care clinic or hospital, in the general community, etc.
    • Participants: Indicate the number of study subjects and how they were selected, recruited, and assigned to the intervention.
    • Intervention: Report the method of administration and duration of the intervention.
  • Results: Provide the main outcomes of the study including confidence intervals or P values. Report the absolute values and risk differences so that readers can determine the absolute, as well as the relative, impact of the results.
  • Conclusions: State only conclusions that are directly supported by the evidence and the implications of the findings.
  • Keywords: Include 3 to 4 keywords associated with your manuscript, separated by semicolons (eg, active vitamin D; parathyroid hormone-related peptide; hypercalcemia; bone resorption). The keywords should be different than the words in the title of your manuscript. Should your manuscript be accepted, the keywords will appear with the published manuscript, making it easier to find in literature search engines such as PubMed.


Body of Paper
In addition to the main content of your manuscript, be sure to include the following (if applicable):
  • Describe ethical guidelines followed (for human or animal studies).
  • Cite approval of institutional human research review committee or animal welfare committee; describe in detail hazardous procedures or chemicals involved, including precautions observed.
  • For studies that are quality improvement (QI) related, authors must include a statement about institutional review board (IRB) review in the Methods section. Authors must include 1 of 2 statements: (1) This study received IRB approval (and include the protocol number); or (2) This study was exempt from IRB review after institutional IRB review.
  • Outline statistical methods used.
  • When describing the results of hypothesis testing, report P values and/or confidence intervals; avoid using phrases such as "not significant."
  • Identify drugs and chemicals used by generic name (if trademarks are mentioned, manufacturer name and city are given).
  • All gene and protein names must be written according to NCBI or HUGO nomenclature.


DEI
Gastroenterology envisions a scientific publishing enterprise that upholds the highest standard of inclusive language and equitable research practice. The Journal has adopted the Sex and Gender Equity in Research (SAGER)(https://researchintegrityjournal.biomedcentral.com/articles/10.1186/s41073-016-0007-6/tables/1) guidelines for sex and gender research reporting. [Accordingly, if only one sex is included in the study, or if the results of the study are to be applied to only one sex or gender, the title and the abstract should specify the sex of animals or any cells, tissues and other material derived from these and the sex and gender of human participants.] Please review to ensure consistent reporting of sex and gender throughout the publication.

The Journal has also adopted updated recommendations from the 11th edition of the AMA Manual of Style (https://academic.oup.com/amamanualofstyle/book/27941/chapter-abstract/207567296?redirectedFrom=fulltext#362714659), including capitalizing race and ethnic identity designations, e.g. Black and White, and use of person-first language (e.g. Black participants rather than Blacks),?and authors of original reports are encouraged to collect and provide disaggregated data that specifically evaluate individual racial, ethnic, and other groups as appropriate. Of note, the terms White or European descent are preferred over Caucasian given the frequent misuse of this term and historical roots in white supremacist ideology. The methods and specific groups included in data collection should be described in the analyses even if numbers are sparse, to enable transparent assessment of the inclusiveness of research studies. Race conscious language should be used in risk assessment tools, acknowledging race as a social construct and social determinants of health as the driving force of racial disparities detected in human subjects research.

Submissions to Gastroenterology will be reviewed for consistency with these SAGER and AMA guidelines.

References
Each submission must include the references used numbered according to first appearance in the text. The in-text citations should be superscript Arabic numerals. Please be sure to cite personal communications and unpublished data parenthetically in the text without numbering. Gastro Hep Advances encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your reference list. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add "[dataset]" immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article. All abbreviations should follow the Index Medicus abbreviations. Please ensure your references follow Gastro Hep Advances style requirements:
  • Article: (list 3 authors, followed by et al): 13. Meltzer SJ, Ahnen DJ, Battifour H, et al. Protooncogene abnormalities in colon cancers and adenomatous polyps. Gastroenterology 1987;92:1174-1180.
  • Book: 18. Day RA. How to write and publish a scientific paper. Philadelphia: Institute for Scientific Information, 1979.
  • Article in book: 22. Costa M, Furness JB, Llewellyn-Smith IF. Histochemistry of the enteric nervous system. In: Johnson LR, ed. Physiology of the gastrointestinal tract. Volume 1. 2nd ed. New York: Raven, 1987:1-40.
  • [dataset] 5. Oguro M, Imahiro S, Saito S, et al. Mortality data for Japanese oak wilt disease and surrounding forest compositions, Mendeley Data, v1; 2015. http://dx.doi.org/10.17632/xwj98nb39r.1


For all revised manuscripts, the corresponding and first author must check each citation listed in the References section.

Tables
Tables may either be uploaded separately or included at the end of the manuscript document. Tables must be provided in an editable format (eg, Microsoft Word, Microsoft Excel); they should not be embedded as an image file. Most table editor programs can be placed within the manuscript file successfully. Tables should be prepared without the use of tabs.

Figures
Please use the following guidelines when preparing figures for Gastro Hep Advances. For more information, please see Gastroenterology's Figure Submission FAQs.
  • Images: All figures should be of high quality (300 ppi or greater when set to the size you would want the figure to print legibly).
    • Multiple panel figures: Please submit all panels together in a single attachment.
  • Acceptable formats: Please submit figures as separate attachments in JPEG, TIFF, EPS, or PDF formats (300 ppi resolution).
    • Figures should not be created in programs such as Word or PowerPoint. Images become compressed when embedded in these programs and will not be as clear and high resolution as the originals. Software such as Adobe Illustrator should be used for figure creation. For questions regarding the conversion of other file formats to JPEG or TIFF, please view Gastroenterology's Figure Submission FAQs.
  • Font: Text presented in figures should be 8 to 10 point sans serif (preferably Arial or Helvetica) but may not go below 6 point or above 13 point, except for panel labels. Panel labels must be 16 point Arial bold letters (A, B, C). Please avoid placing panel labels over images.
  • Photographs: Remove all names and all other patient identifiers from photos and radiographic studies.
  • Line art and graphs: AGA reserves the right to reformat and/or redraw graphs, charts, and other line art to ensure stylistic consistency across AGA Institute journals. Please ensure that any graphs or line art are submitted in at least 300 ppi resolution. 3D-style art is not accepted.
  • Figure legends: Please do not embed or flatten the text into the image files. Figure legends should be included at the end of the manuscript body. AGA staff reserves the right to reformat to ensure stylistic consistency across AGA Institute journals.
  • Gel electrophoresis labels: Protein molecular weight or DNA marker sizes must be indicated on all figure panels showing gel electrophoresis.
  • File naming: Figures should be named consecutively, such as "figure 1.tif," "figure 2.jpg," etc, with the file extension appended (.tif, .jpg, .eps, etc). Each figure should be saved as a separate electronic file.
  • Color files: Figures should be submitted in the CMYK color space. Authors are encouraged to present color figures in a manner that will allow the data to be interpreted by ree readers. Gastroenterology suggests that authors present dual-labeled images in green and magenta rather than in green and red. See the website of the Jfly data depository for Drosophila researchers (http://jfly.iam.u-tokyo.ac.jp/color/) for more information on how to make figures and presentations intelligible for a colorblind audience.


Supplemental Material
We encourage you to submit nonessential figures or portions of your manuscript as supplementary material, as this is highly beneficial to our readership. Authors who offer supplementary information must ensure those materials are readily available upon request. However, please note that the following items MUST be within the main text and not provided as supplemental information:
  • "Materials and Methods" section
  • References cited within the main text


Exceptions to this rule include tables of primers or antibodies with legends in such tables describing details of the use of such reagents.

The portions of your manuscript that you would like to be included as supplementary material (including figures and tables) should be uploaded separately from the manuscript as "supporting documents."

PREPRINT SERVER POLICY

Gastro Hep Advances allows manuscript submissions to have been posted to a preprint server, with the following stipulations:
  • The preprint cannot be updated while the manuscript is under review and cannot be updated if it is accepted for publication in the journal, even if the preprint server directs the author to do otherwise.
  • If a manuscript is already submitted to an AGA journal and is under review, that manuscript may be submitted to a preprint server at any time before the article is accepted so that it may be considered as a published work in grant applications. As above, that preprint cannot be edited or updated while under review and cannot be updated if it is accepted for publication in the journal.
  • Publication of a preprint must be noted on the title page of the submission, with the preprint DOI included.
  • Because of the potential impact on patient care, preprints of a clinical nature are discouraged but will be considered; your decision to post a clinically oriented paper to a preprint server may affect ultimate acceptance.
  • We allow submissions of preprint papers only from platforms that allow you to update your record with a link to the published article (eg, bioRxiv).


DATA TRANSPARENCY POLICY

Gastro Hep Advances is committed to supporting the transparency, openness, and reproducibility of science; to that end, the journal has developed a comprehensive data transparency policy to help authors develop their manuscripts in a manner that advances this goal. The policy is inclusive of clinical, basic, and translational research and was developed with the guiding principles set forth by the International Committee of Medical Journal Editors (ICMJE) and the Center for Open Science (COS).

CLINICAL RESEARCH

Data Citation
Gastro Hep Advances requires authors to cite underlying or relevant datasets in their manuscript by citing them in the text and including a data reference in the reference list. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add "[dataset]" immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

Data, Materials, and Code
Gastro Hep Advances requires authors to indicate whether the data, methods used in the analysis, and materials used to conduct the research will be made available to any researcher for purposes of reproducing the results or replicating the procedure. Authors must, in a "Data Transparency Statement" on the title page, indicate if they will or will not make their data, analytic methods, and study materials available to other researchers. If an author agrees to make materials available, the author must specify where that material will be available.

Transcript profiling (expression microarray) data must be submitted to an appropriate repository (either NCBI's GEO or EBI's ArrayExpress). The data preferably should be MIAME compliant (http://fged.org/projects/miame/). The repository URL and the data accession number must be included, both in the body of the manuscript and in Editorial Manager, upon submission. The full dataset must be available to reviewers either via a download link or on a data disk (5 copies). Gastro Hep Advances requires all meta-analyses of genetic studies to follow the Human Genome Epidemiology Network (HuGENet) guidelines. To review the guidelines, go to https://www.cdc.gov/genomics/hugenet/participate.htm#guidelines.

Other large datasets produced using genomics technologies (including but not limited to ChIP on Chip, Genotyping, and Tilling Arrays) must be deposited in an appropriate public repository. The repository URL and the data accession number must be included, both in the body of the manuscript and in Editorial Manager, upon submission. If there is no public repository for the submitted data, it is the author's responsibility to provide permanent publicly accessible links to the raw data and access for the reviewers.

Authors must also furnish information about the identity and purity of new chemical compounds. Experimental details and characterization data should be provided in either the main text or as supplemental material. Experimental details should be sufficient to allow other researchers to reproduce the synthesis of the compound.

Design and Analysis
Gastro Hep Advances requires authors to follow standards for disclosing key aspects of the research design and data analysis. Authors are encouraged to review the standards available for many research applications from https://www.equator-network.org/ for the reported research applications. For transcript profiling data, please refer to the MIAME guidelines (http://fged.org/projects/miame/).

Preregistration of Studies and Analyses
Gastro Hep Advances requires authors to indicate whether the conducted research was preregistered with an analysis plan in an independent, institutional registry (eg, http://clinicaltrials.gov/, http://openscienceframework.org/, http://ridie.3ieimpact.org/). Preregistration of studies involves registering the study design, variables, and treatment conditions. Including an analysis plan involves specification of sequence of analyses or the statistical model that will be reported.

Authors must, in a "Data Transparency Statement" on the title page, indicate if they did or did not preregister the research with or without an analysis plan in an independent, institutional registry. If an author did preregister the research with an analysis plan, the author must do the following:
  • Confirm in the text that the study was registered prior to conducting the research with links to the time-stamped preregistrations at the institutional registry and that the preregistration adheres to the disclosure requirements of the institutional registry or those required for the preregistered badge with analysis plans maintained by the Center for Open Science.
  • Report all preregistered analyses in the text, or, if there were changes in the analysis plan following preregistration, disclose those changes and include an explanation for the changes.
  • Clearly distinguish in the text the analyses that were preregistered from those that were not, such as having separate sections in the results for confirmatory and exploratory analyses.


Replication
Gastro Hep Advances encourages submission of replication studies, particularly of research published in this journal.

Clinical Trials
Data Sharing
Gastro Hep Advances requires that clinical trial reports address the authors' intent to share deidentified individual participant data. To that end, authors must include a data sharing statement on the title page under the heading "Data Transparency Statement." The statement should include the following information:
  • Whether deidentified individual participant data will be shared
  • Which particular data will be shared
  • Any additional documents that will be shared
  • The method through which data will be shared
  • The time frame during which data will be accessible
  • The conditions, if any, required to access to the data
  • Deidentified individual participant data are available indefinitely at www.example.org. The study protocol, analytic code?[etc] are also available at the same website.
  • Deidentified individual participant data that underlie the reported results will be made available 3 months after publication for a period of 5 years after the publication date at www.example.org. Proposals for access should be sent to [email protected] The study protocol is included as a data supplement available with the online version of this article.
  • Individual participant data will not be shared.


Registration
In accordance with the guidelines set for by ICMJE, authors of manuscripts involving clinical trials must provide full registration of their trial(s). A clinical trial is defined as any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. The trial must have at least 1 prospectively assigned concurrent control or comparison group in order to trigger the requirement for registration. Appropriate online registries include https://clinicaltrials.gov/, http://www.isrctn.com/, http://www.umin.ac.jp/ctr/index.htm, http://www.anzctr.org.au/,http://www.trialregister.nl/trialreg/index.asp, or any primary registry that participates in the World Health Organization's International Clinical Trial Platform.

When submitting your manuscript via Editorial Manager, you must adhere to the following guidelines:
  • Please include the clinical trial registry website and trial number at the end of the "Conclusions" section of the abstract in the manuscript Word document (this information will not count toward the 260 word limit). Example: ClinicalTrials.gov number, NCT002209456.
  • Please include a statement in the "Methods" section of the manuscript that affirms all authors had access to the study data and reviewed and approved the final manuscript.
  • Please upload the clinical trial study protocol as a separate attachment.


Randomized Controlled Trials
Randomized controlled trials should be presented according to the CONSORT guidelines. Manuscripts that do not adhere to these guidelines will not be reviewed for publication.
When submitting your manuscript via Editorial Manager, you must adhere to the following guidelines:
  • Please complete and upload as a separate attachment the CONSORT flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal, and completion, and a detailed description of the randomization procedure. The CONSORT template flow diagram can be found at http://www.consort-statement.org.
  • Please complete and upload as a separate attachment the CONSORT checklist, which you can find at http://www.consort-statement.org.


BASIC AND TRANSLATIONAL RESEARCH

Data Citation
Gastro Hep Advances requires authors to cite underlying or relevant datasets in their manuscript by citing them in the text and including a data reference in the reference list. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add "[dataset]" immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

Data, Materials, and Code

Gastro Hep Advances requires authors to indicate whether the data, methods used in the analysis, and materials used to conduct the research will be made available to any researcher for purposes of reproducing the results or replicating the procedure. Authors must, in the acknowledgments, indicate if they will or will not make their data, analytic methods, and study materials available to other researchers. If an author agrees to make materials available, the author must specify where that material will be available.

Transcript profiling (expression microarray) data must be submitted to an appropriate repository (either NCBI's GEO or EBI's ArrayExpress). The data should preferably be MIAME compliant (http://fged.org/projects/miame/). The repository URL and the data accession number must be included, both in the body of the manuscript and in Editorial Manager, upon submission. The full dataset must be available to reviewers either via a download link or on a data disk (5 copies). Other large datasets produced using genomics technologies (including but not limited to ChIP on Chip, Genotyping, and Tilling Arrays) must be deposited in an appropriate public repository. The repository URL and the data accession number must be included, both in the body of the manuscript and in Editorial Manager, upon submission. If there is no public repository for the submitted data, it is the author's responsibility to provide permanent publicly accessible links to the raw data and access for the reviewers.

Authors must also furnish information about the identity and purity of new chemical compounds. Experimental details and characterization data should be provided in either the main text or as supplemental material. Experimental details should be sufficient to allow other researchers to reproduce the synthesis of the compound.

Design and Analysis
Gastro Hep Advances requires authors to follow standards for disclosing key aspects of the research design and data analysis. Authors are encouraged to review the standards available for many research applications from http://www.equatornetwork.org/ and use those that are relevant for the reported research applications. For transcript profiling data, please refer to the MIAME guidelines (http://fged.org/projects/miame/).

Replication
Gastro Hep Advances supports publication of replication studies that address topics of significant scientific value. Authors of such studies are encouraged to submit them to the journal for consideration for publication.

GRAPHICAL ABSTRACTS

A graphical abstract is a single, concise visual summary of the main findings of the article. For ease of understanding, the graphical abstract should read clearly from top to bottom or left to right.

Specifications
Please download and use our PowerPoint template to assist in the creation of your graphical abstract. The template file is the proper size and contains the required font style and size, plus other stylistic elements to ensure a clean and uniform look to your abstract. If you elect not to use our template, please adhere to the following guidelines:
  • Image size: Minimum of 2 inches high by 5 inches wide at 300 ppi. Larger images are allowed, but please use the same ratio (2 inches high by 5 inches wide). Please note that your image will be scaled proportionally to fit in a 2-inch by 5-inch rectangle.
  • Font: Arial font only will be accepted.
  • File type: Preferred file types are TIFF, EPS, PDF, or PowerPoint.
  • No additional text, outline, or synopsis can be included. Any text or label must be part of the image file. Please do not use unnecessary white space or the heading "Graphical Abstract" within the image file.


Style
Graphical abstracts must satisfy the following requirements:
  • Be a clear, visual representation of the main findings of the article
  • Use text sparingly
  • Avoid distracting or cluttering components
  • Use color, as appropriate


Color
The use of color is encouraged; however, graphical abstracts are subject to the same color figure charges as the rest of your article. If you do not wish to have your graphical abstract printed in color, please provide 2 versions-1 in color for online publication only and 1 in black and white/grayscale for publication in print.

Graphics Support
The editorial office is not able to provide graphics support at this time. Authors are responsible for obtaining permission to use any images that they include from outside sources, including articles, web pages, stock photo sites or Google image searches. Any needed permissions must be submitted along with your graphical abstract or identified in the Acknowledgments section of your manuscript.

MANUSCRIPT PROCESSING AND REVIEW

Submissions
Submit your manuscript via Editorial Manager (http://www.editorialmanager.com/ghadvances). Each new manuscript receives a unique number and information on the manuscript is recorded on our internal network. Editorial staff may only release information on manuscripts to the corresponding author(s). The editorial office will email a letter to the corresponding author to acknowledge receipt of a new or revised manuscript. Editors and editorial staff are not able to answer any presubmission inquiries from authors.

Review process
Each manuscript is assigned to an associate editor who has expertise on the subject. If the manuscript is judged to be appropriate and competitive for publication by the associate editor, it is sent to experts in the appropriate area for peer review. The associate editor chooses at least 2 reviewers, who remain anonymous. Authors are encouraged to suggest an associate editor and 4 to 6 reviewers in the cover letter, though final assignments are at the discretion of the handling editor.

Reviewers provide comments for the editor and for the authors. The journal expects reviewers to treat manuscripts as confidential communications and to not use the content for their own purposes or make copies of the manuscripts. Reviewers are also expected to declare to the editor any possible conflicts of interest.

Decisions
A core objective is to publish papers cascaded from AGA's other journals that represent outstanding science and therefore qualify for publication in a journal supported by the AGA brand. Compared with other journals in the AGA portfolio, Gastro Hep Advances is less concerned with novelty and subjective perceptions of significance, but rather is more interested in publishing all research that is technically, ethically, and scientifically sound. Decision letters usually, but not always, convey all factors considered for a particular decision. Occasionally, the comments to the authors may appear to be inconsistent with the editorial decision, which takes into consideration reviewers' comments to the editor, and the additional factors listed above.
Decisions on peer-reviewed papers are emailed to the authors an average of 3 weeks from the date of submission. We make every effort to contact authors within 3 to 7 days for manuscripts that are rejected internally without review. All manuscripts are evaluated promptly by at least 2 members of the board of editors prior to making such decisions.

APPEALS POLICY

The AGA values the opinions of its editors and reviewers and strongly discourages appeals, however if you believe your submission was rejected because the editors misunderstood it or there was unethical conduct in the peer-review process, you may submit an appeal. Please note the AGA journals do not accept appeal requests for manuscripts that were not externally peer reviewed.
  • Your appeal request will be processed by the Gastro Hep Advances managing editor. The appeal request will then be considered by the journal's editor-in-chief, who may seek input from the original submission's associate editor.
    • If the reason you are submitting an appeal is complex and requires an objective third-party evaluation, your appeal will instead be reviewed by the chair of the AGA Publications Committee and the relevant editorial staff.
  • There are several outcomes that could arise from your appeal request, including an invitation to revise, the upholding of the original decision, or an alternate course of action.
  • The editorial office will aim to provide the results of your appeal request back to you within two weeks, however there may be variation based on the complexity of the appeal. Please note that all decisions arising from an appeal request are considered final.


PUBLICATION

We will forward your unedited manuscript to our publisher for posting to the Articles in Press section of our website. Your article should be posted within 2 to 3 days of receipt of files.

The publisher will forward page proofs to you for your final review within 4 to 6 weeks. The final version of your paper will be published online once proof corrections have been received.

Our medical illustration staff may redraw or reformat line art and graphs for publication quality or contact you if higher quality versions are needed. Please be sure to carefully review your figures when you receive your publication proofs.

There is a press embargo for all studies published in Gastro Hep Advances until they are posted online in our Articles in Press section. Please forward your acceptance email to your institution press officer for promotional consideration. We ask that your public relations contacts share promotion plans and/or address any questions to [email protected]. Please see our embargo policy at www.ghadvancesjournal.org/content/embargo for more details.

Manuscripts are copyedited to make them consistent with journal style; if a particular section in the manuscript is not clear or requires additional information, the copy editor will direct questions to the author. These questions, or "author queries," will appear in the article proofs that are provided to the corresponding author.

Authors are required to return proofs to the publisher within 48 hours. If changes are not returned within 48 hours, the manuscript will move forward in the production process.

Publication Fees
For papers that are accepted for publication, authors will be charged a publication fee. For full-length original research and reviews type articles, if the corresponding or first author is an AGA member, the fee is $1400. Nonmembers pay $2000. For short communications, including case reports, the open access fee is $700 for members and $1000 for nonmembers. For images of the month, the fee is $350 for members and $500 for nonmembers. Cases of hardship will be considered on an individual basis.

Licensing Options
Gastro Hep Advances offers authors the choice of different forms of Creative Commons licenses that will allow others to make use of the published work. Authors must select the type of license at the time of submission. An overview of these licenses is included below. For more detailed information, please go to https://www.elsevier.com/openaccesslicenses.

Creative Commons Attribution-NonCommercial-NoDerivs (CC-BY-NC-ND): Allows others to access and download an article and share it with others as long as they credit the author (and do not represent the author as endorsing their work), but they cannot change the article in any way or use it commercially.

ETHICAL STANDARDS

Gastro Hep Advances strongly discourages the submission of more than 1 article dealing with related aspects of the same study. In almost all cases, a single study is best reported in a single paper.

The journal editors consider research/publication misconduct to be a serious breach of ethics and will take action as necessary to address such misconduct, which includes submission or publication of information that
  • is intentionally erroneous,
  • has been published elsewhere by a different author without acknowledgment (plagiarism),
  • has been published elsewhere by the same author without acknowledgment (duplicate publication), or is subsequently published elsewhere by the same author without acknowledgement.


The publication of abstracts or posters is not considered duplicate publication but should be disclosed in the cover letter accompanying the manuscript submission.

Each author who submits a manuscript to Gastro Hep Advances must attest to several author statements in the manuscript management system, thereby affirming authorship responsibility, manuscript originality, payment of author fees, IRB/animal care committee approval, role of study sponsor, financial disclosures, and funding sources.

Breaches of Gastro Hep Advances' ethical standards may result in proscribed submission for all authors of the concerned manuscript and, when appropriate, notification of the authors' institutions. All authors are fully responsible for the content of the manuscript.

Animal Experiments
For any manuscripts that include data from animal experiments, Gastro Hep Advances requires authors to adhere to standards articulated in the Animal Research: Reporting of In Vivo Experiments (ARRIVE) (https://www.nc3rs.org.uk/arrive-guidelines) guidelines. In addition, in the Methods section of the manuscript text, authors must include the following:
  • A statement of adherence to the above referenced standards
  • A statement of institutional approval
  • All relevant animal experimental information
    • Sex and age of mice (or other in vivo models) for all the experiments
    • The genetic background(s) of the mice or other experimental in vivo models
    • For transgenic or genetic mouse models, whether the controls were sibling littermates or were purchased separately (if purchased separately, were the animals cohoused to minimize potential effects of different microbiota)
    • Specifics of diet composition
    • Whether mice were fasted (and for how long) before a challenge or an assessment was carried out
    • Type of bedding, caging system, and enrichment used for housing the mice
    • If interventions were performed, whether they were done during light or dark cycle


Any deviation from these standards or practices must be described in detail. Please refer to Gastroenterology's commentary for comprehensive information.

Authorship
Each author must have participated sufficiently in the work to take public responsibility for the content of the paper and must approve of the final version of the manuscript. Authorship should be based on substantive contributions to each of the following:
  • conception and design of the study
  • generation, collection, assembly, analysis and/or interpretation of data
  • drafting or revision of the manuscript
  • approval of the final version of the manuscript


CONFLICT OF INTEREST POLICY

Potential Conflicts of Interest
The following are examples of conflicts of interest (COI) that may occur with editors, authors (including invited authors), and reviewers. Interactions considered pertinent are from the start of the research activity in a specific program until such time that a submission is anticipated to be published or 1 year from submission date, whichever is longer.
  • Editors: Editors who make final decisions about manuscripts must have no personal, professional, or financial involvement in any of the issues they might judge. Examples of personal involvement with an author include former students, fellows, mentors, or relatives. Examples of professional involvement include academic rivalry, being from the same institution or research group as the author, evaluating a manuscript submitted by a member of the board of editors, or collaborating (eg, coauthoring research article or grant) with an author. Examples of financial involvement include employment, consultancies, honoraria, stock ownership or options, expert testimony, grants/patents received, and royalties with an entity (or competing entity) discussed in the manuscript.
    • It is a COI for editors of the AGA Institute journals to hold a position of editorial responsibility for a competing publication. The ethics committee reviews disclosure statements submitted by editors and notifies either/both the secretary/treasurer and editor of any potential COI. The procedures contained in Section C of the "AGA/AGA Institute Policy on Disclosure of Potential Conflict of Interest" apply if a COI is found to exist.
  • Authors: COIs for an author may arise if there exists a financial arrangement (eg, employment, consultancies, honoraria, stock ownership or options, expert testimony, grants/patents received, and royalties) with a company whose product figures prominently in the submitted manuscript or with a company that makes a competing product.
  • Reviewers: COIs for reviewers exist when they have had an ongoing collaboration, original publications, or grants with the authors within the previous 2 years, except when part of a multicenter group from a different site; are from the same institution as the authors; or have any financial arrangements (eg, employment, consultancies, honoraria, stock ownership or options, expert testimony, grants/patents received, and royalties) with a company whose product figures prominently in the submitted manuscript or with a company that makes a competing product.


Process
Potential COIs are to be disclosed at the beginning of the peer-review process.
  • Editors: An associate editor having a COI with a submitted manuscript must recuse himself from handling the manuscript and request that the manuscript be reassigned. The editor-in-chief having a COI with a submitted manuscript must assign its review to an associate or guest editor for handling. A manuscript submitted by a member of the board of editors must be assigned to a guest editor.
  • Authors: The senior or corresponding author assumes full responsibility for supplying the following information on the title page at manuscript submission:
    • For each author, disclosure of any financial arrangement with any company whose product figures prominently in the submitted manuscript or that makes a competing product; or a statement for each author that there is no conflict to disclose.
    • A disclosure of all funding sources supporting the work and all institutional or corporate affiliations.
    • A list of individuals who provided writing assistance for the manuscript and the source of funds that supported this assistance.
    • In addition, at manuscript submission, each author must attest to several author statements in the manuscript management system, thereby affirming authorship responsibility, manuscript originality, payment of author fees, IRB/animal care committee approval, role of study sponsor, financial disclosures, and funding sources.
    • Based on the information provided, the editors will determine whether a COI exists and decide to either: (1) reject the manuscript or (2) publish the manuscript with the COI disclosed.
  • Reviewers: When invited, reviewers must decline to review a manuscript if a potential COI exists. After review, reviewers must answer the following questions, which appear in the journals' manuscript tracking system:
    • Have you, the undersigned reviewer, had an ongoing collaboration, original publication, or grant with the authors within the previous 2 years, except in the case of being a part of a multicenter group from a different site?
    • Are you, the undersigned reviewer, from the same institution as the authors?
    • Do you, the undersigned reviewer, have any financial arrangements (eg, employment, consultancies, honoraria, stock ownership or options, expert testimony, grants/patents received, and royalties with an entity) with a company whose product figures prominently in the submitted manuscript or with a company making a competing product? Any reviewer answering "yes" to this question is prompted to describe the nature of their financial agreements.
    • If the reviewer discloses a potential COI after the review, the handling associate editor decides if the review should still be used to judge the manuscript.


Sanctions
Should an editor, author, or reviewer fail to disclose a potential COI and it is discovered after publication, the following sanctions may be applied according to the severity of the infraction:
  • Editors:
    • A letter of reprimand and warning as to future conduct from the editor-in-chief, in the case of an associate editor, or from the chair of the publications committee, in the case of the editor-in-chief
    • Dismissal from the position
  • Authors:
    • A letter from the editor of explanation and education where there appears to be a genuine misunderstanding of principles
    • A letter from the editor of reprimand and warning as to future conduct
    • A letter from the editor to the author's institution or funding body
    • Publication of a notice detailing the author's failure to disclose the COI
    • Publication of an editorial detailing the full details of the misconduct
    • Refusal to accept future submissions from the author on a sliding scale of 1 to 5 years
    • Formal retraction or withdrawal of the paper from the scientific literature
    • Reporting the case to the Office of Research Integrity (ORI)
  • Reviewers:
    • A letter from the editor of explanation and education where there appears to be a genuine misunderstanding of principles
    • A letter from the editor of reprimand and warning as to future conduct
    • A letter from the editor to the reviewer's institution
    • Refusal to allow the individual to review for the journal on a sliding scale of 1 to 5 years


This policy was developed in accordance with the guidelines set forth by the Committee on Publication Ethics (COPE) and the International Committee of Medical Journal Editors (ICMJE).

PLAGIARISM, DUPLICATE SUBMISSION/PUBLICATION POLICY

Definitions
  • Plagiarism is the unreferenced use of published and unpublished ideas. It may occur at any stage of planning, research, writing, or publication and applies to print and electronic versions.
  • Duplicate submission/publication occurs when 2 or more papers, without full cross-reference, share the same hypothesis, data, discussion points, or conclusions.


Sanctions
Should plagiarism or duplicate submission/publication be identified, the journal editors will apply the sanctions listed below according to the severity of the infraction. They will apply sanctions to individual authors depending on their type of involvement with the article, as provided at the time of submission on the title page.
  • A letter of explanation from the journal editors to the authors where there appears to be a genuine misunderstanding of principles
  • A letter of reprimand from the journal editors as to future conduct
  • A formal letter from the journal editors to the author's institution, employer, or funding body
  • Publication of a notice or editorial in the journal
  • Refusal to accept submissions from the author for a range of 1 to 5 years
  • Formal withdrawal or retraction of paper from the scientific literature
  • Journal editors report the case to Office of Research Integrity, which promotes integrity in biomedical and behavioral research supported by the US Public Health Service; monitors institutional investigations of research misconduct; and facilitates the responsible conduct of research through educational, preventive, and regulatory activities


This policy was developed in accordance with the guidelines set forth by COPE and ICMJE.

IMAGE MANIPULATION POLICY

Definition*
Image manipulation is the misrepresentation of data by selectively altering portions of an image. The expectations for how images should be handled ethically are as follows:
  • No specific feature within an image may be enhanced, obscured, moved, removed, or introduced.
  • The grouping of images from different parts of the same gel or from different gels, fields, or exposures must be made explicit by the arrangement of the figure (eg, using dividing lines) and in the text of the figure legend.
  • Adjustments of brightness, contrast, or color balance are acceptable if they are applied to every pixel in the image and as long as they do not obscure, eliminate, or misrepresent any information present in the original, including backgrounds. Nonlinear adjustments (eg, changes to gamma settings) must be disclosed in the figure legend.


*Language used with permission from The Journal of Cell Biology.

Process
Journal graphics staff will screen images at random during the submission process and will review images that editors, reviewers, or readers suspect have been manipulated. If manipulation is suspected, the staff and editors will initiate an investigation with the authors and possibly their institutions.

Sanctions
Should image manipulation be verified before or after publication of an article, one of the below sanctions will be applied, based on the severity of the infraction. The editor-in-chief and Board of Editors will determine, on a case-by-case basis, the severity of the infraction and corresponding sanction. Sanctions will be applied to individual authors depending on their type of involvement with the article, as provided at the time of submission on the title page.
  • A letter of explanation from the journal editors to the authors where there appears to be a genuine misunderstanding of principles
  • A letter of reprimand from the journal editors as to future conduct
  • A formal letter from the journal editors to the author's institution or employer
  • Rejection or withdrawal of manuscript acceptance
  • Publication of a correction or editorial
  • Retraction of the published article
  • Refusal to accept submissions from the author for a range of 1 to 5 years. For particularly egregious cases or series of cases, a lifetime ban may be considered.


The AGA reserves the right, on a case-by-case basis, to report particularly egregious cases to relevant funding bodies. This policy was developed in accordance with the guidelines set forth by COPE.

OPEN ACCESS POLICIES

Compliance With Funders' Open Access Policies
Gastro Hep Advances' publishing partner, Elsevier, has established agreements and developed policies to allow authors who publish in Elsevier journals to comply with manuscript archiving requirements of various funding bodies (eg, the National Institutes of Health) as specified as conditions of researcher grant awards. For a full list of funding bodies with which Elsevier has agreements, go to https://www.elsevier.com/about/open-access/open-access-policies/funding-body-agreements. These agreements and policies enable authors to comply with their funding body's archiving policy without having to violate their publishing agreements with Gastro Hep Advances. The agreements and policies are intended to support the needs of the journal's authors, editors, and society publishing partners, and to protect the quality and integrity of the peer-review process.

Manuscript Posting
Authors of articles published in Gastro Hep Advances may voluntarily post their accepted manuscripts to personal websites or institutional repositories immediately upon acceptance.

CLINICAL TRIALS

Registration
In accordance with the guidelines set for by ICMJE, authors of manuscripts involving clinical trials must provide full registration of their trial(s). A clinical trial is defined as any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. The trial must have at least 1 prospectively assigned concurrent control or comparison group in order to trigger the requirement for registration. Appropriate online registries include https://clinicaltrials.gov/, http://www.isrctn.com/, http://www.umin.ac.jp/ctr/index.htm, http://www.anzctr.org.au/, http://www.trialregister.nl/trialreg/index.asp, or any primary registry that participates in the World Health Organization's International Clinical Trial Platform.

When submitting your manuscript via Editorial Manager, you must adhere to the following guidelines:
  • Please include the clinical trial registry website and trial number at the end of the "Conclusions" section of the abstract in the manuscript Word document (this information will not count toward the 260 word limit). Example: ClinicalTrials.gov number, NCT002209456.
  • Please include a statement in the "Methods" section of the manuscript that affirms all authors had access to the study data and reviewed and approved the final manuscript.
  • Please upload the clinical trial study protocol as a separate attachment.


Randomized Controlled Trials
Randomized controlled trials should be presented according to the CONSORT guidelines. Manuscripts that do not adhere to these guidelines will not be reviewed for publication.

When submitting your manuscript via Editorial Manager, you must adhere to the following guidelines:
  • Please complete and upload as a separate attachment the CONSORT flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal, and completion, and a detailed description of the randomization procedure. The CONSORT template flow diagram can be found at http://www.consort-statement.org.
  • Please complete and upload as a separate attachment the CONSORT checklist, which you can find at http://www.consort-statement.org.


REPORTING META-ANALYSES OF GENETIC STUDIES

Gastro Hep Advances requires all meta-analyses of genetic studies to follow the Human Genome Epidemiology Network (HuGENet) guidelines. To review the guidelines, go to http://www.cdc.gov/Genomics/hugenet/default.htm.

DISTRIBUTION OF MATERIALS DESCRIBED IN PUBLISHED PAPERS

Authors are expected to make available materials such as cell lines, cDNA clones, hybridomas, antibodies, biological reagents, unique animals, etc, to any qualified investigator. Prior to the submission of newly cloned genes or nucleic acid sequences, the journal requires authors to provide an accession number to a publicly accessible, recognized data repository (eg, GenBank) on the title page of the manuscript.

Transcript profiling (expression microarray) data must be submitted to an appropriate repository (either NCBI' GEO or EBI's ArrayExpress). The data preferably should be MIAME compliant (http://fged.org/projects/miame/). The repository URL and the data accession number must be included, both in the body of the manuscript and in Editorial Manager, upon submission. The full dataset must be available to reviewers either via a download link or on a data disk (5 copies).

Other large datasets produced using genomics technologies (including but not limited to ChIP on Chip, Genotyping, aCGH, and Tilling Arrays) must be deposited in an appropriate public repository. The repository URL and the data accession number must be included, both in the body of the manuscript and in Editorial Manager, upon submission. If there is no public repository for the submitted data, it is the author's responsibility to provide permanent publicly accessible links to the raw data and access for the reviewers.

Authors must also furnish information about the identity and purity of new chemical compounds. Experimental details and characterization data should be provided in either the main text or as supplemental material. Experimental details should be sufficient to allow other researchers to reproduce the synthesis of the compound.

These guidelines are a means of encouraging the free exchange of scientific information and to promote progress in all areas of gastroenterological investigation.